文献速递白血病

急性髓系白血病中CEBPA基因突变的类型及其对预后的影响

[Type of CEBPA mutations in acute myeloid leukemia and their effect on prognosis].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2024-01-01

回顾性分析北京协和医院2016年4月至2022年11月57例CEBPA突变急性髓系白血病患者,bZIP区域框内突变28例、其他CEBPA突变29例;bZIPinf组更年轻、原发AML更常见、骨髓原始细胞更高,1个疗程完全缓解率更高,中位总生存期长于野生型。

要点

  • CEBPA突变占同期353例AML的16.1%,bZIPinf 28例、其他CEBPA突变29例。
  • bZIPinf组较其他CEBPA突变组更年轻(54岁对64岁,P=0.010)、骨髓原始细胞更高(68.0%对36.3%,P=0.001)。
  • bZIPinf组1个疗程完全缓解率87.5%,高于其他CEBPA突变组47.4%和野生型组50.3%。

核心结论

  • CEBPA-bZIPinf突变的AML患者具有独特的临床特征,对化疗的反应更好,预后更佳。

研究设计与样本

  • 回顾性分析2016年4月至2022年11月北京协和医院确诊的57例伴有CEBPA基因突变的AML患者的人口学信息、临床表现、实验室检查结果、治疗及生存数据。

主要发现

  • 57例CEBPA基因突变患者占同期所有353例AML患者的16.1%,其中CEBPA-bZIPinf 28例,CEBPA-other 29例。
  • 与CEBPA-other患者相比,CEBPA-bZIPinf患者更年轻(54岁对64岁,P=0.010),原发性AML更常见(P=0.001),骨髓原始细胞比例更高(68.0%对36.3%,P=0.001)。
  • CEBPA-bZIPinf及CEBPA-other患者分别有24例和19例接受化疗,CEBPA-bZIPinf患者的1个疗程完全缓解率显著高于CEBPA-other(87.5%对47.4%,P=0.010)及CEBPA野生型(87.5%对50.3%,P=0.002)患者。
  • 中位随访11个月,CEBPA-bZIPinf患者的中位总生存期明显长于CEBPA野生型患者(未达到对22.1个月,P=0.012)。

关键数值与推荐

  • CEBPA-bZIPinf组1个疗程完全缓解率87.5%,CEBPA-other组47.4%(P=0.010),CEBPA野生型组50.3%(P=0.002)。
  • CEBPA-bZIPinf组中位总生存期未达到,CEBPA野生型组22.1个月(P=0.012)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To demonstrate the type of CEBPA gene mutations among patients with acute myeloid leukemia (AML), clinical characteristics, and prognostic effect on patient outcomes. Methods: Demographic data, clinical features, laboratory characteristics, and data about treatment and follow-up of 57 patients with CEBPA mutated AML diagnosed at Peking Union Medical College Hospital between April 2016 and November 2022 were collected and analyzed. Results: In total, 57 patients with CEBPA mutation accounted for 16.1% of all the 353 patients with AML, among which 28 patients had CEBPA-bZIPinf and 29 had CEBPA-other. Compared with the CEBPA-other group, the CEBPA-bZIPinf group was younger (54 vs 64 years, P=0.010), de novo AML was more common (P=0.001), and the level of bone marrow blast was higher (68.0% vs 36.3%, P=0.001). Moreover, 24 patients from the CEBPA-bZIPinf group and 19 from the CEBPA-other group received chemotherapy. The one-course complete remission (CR) rate of the CEBPA-bZIPinf group was significantly higher than that of the CEBPA-other (87.5% vs 47.4%, P=0.010) and CEBPA-wt (87.5% vs 50.3%, P=0.002) groups. After a median follow-up of 11 months, the median OS of the CEBPA-bZIPinf group was significantly longer than that of the CEBPA-wt group (not reached vs 22.1 months, P=0.012) . Conclusion: CEBPA-bZIPinf mutated AML is a unique clinical entity, with a younger age of diagnosis, better response to chemotherapy, and better prognosis. 目的: 探讨携带CEBPA基因突变的急性髓系白血病(AML)患者的突变类型、临床特点和突变对生存结局的影响。 方法: 回顾性分析2016年4月至2022年11月期间北京协和医院确诊的57例伴有CEBPA基因突变的AML患者的人口学信息、临床表现、实验室检查结果、治疗以及生存数据。 结果: 57例CEBPA基因突变患者占同期所有353例AML患者的16.1%,其中bZIP区域框内突变(CEBPA-bZIPinf)28例,其余CEBPA基因突变(CEBPA-other)29例。与CEBPA-other患者相比,CEBPA-bZIPinf患者更年轻(54岁对64岁,P=0.010),原发性AML更常见(P=0.001),骨髓原始细胞比例更高(68.0%对36.3%,P=0.001)。CEBPA-bZIPinf及CEBPA-other患者分别有24例和19例接受化疗,CEBPA-bZIPinf患者的1个疗程完全缓解率显著高于CEBPA-other(87.5%对47.4%,P=0.010)及CEBPA野生型(87.5%对50.3%,P=0.002)患者。中位随访11个月,CEBPA-bZIPinf患者的中位总生存期明显长于CEBPA野生型患者(未达到对22.1个月,P=0.012)。 结论: CEBPA-bZIPinf突变的AML患者具有独特的临床特征,对化疗的反应更好,预后更佳。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Mao YY, Cai H, Cao XX, et al. [Type of CEBPA mutations in acute myeloid leukemia and their effect on prognosis]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39134486. doi:10.3760/cma.j.cn121090-20240316-00098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。